Wednesday, September 7, 2016 Daily Archives

Lonza Releases Second-Generation Immunogenicity Assessment and Optimization Platform for Development of Therapeutic Proteins, Vaccines and Cell Therapies

Lonza, a global leader in biological development and manufacturing, announced today the release of its second-generation immunogenicity assessment platform. The upgraded platform consists of state-of-the-art in silico and in vitro/ex vivo technologies to evaluate immunogenicity risk during the pre-clinical development of therapeutic proteins. In the context of vaccine and cell therapy development, the platform enables the rational design and testing of optimal immune responses in healthy donor or patient populations. This second-generation platform provides a comprehensive toolbox to assess customers’…

S-Bio Launches EZGlyco mAB Kit with 2-AB for N Glycan Sample Preparation from IgG in cell culture for HPLC analysis

S-BIO1 has launched today EZGlyco™ mAb-N Kit with 2-AB, a breakthrough new product that enables scientists to analyze N -glycans in IgG and Fc-fusion proteins from culture supernatant samples in a rapid, simplified and streamlined single tube operation. The kit is a valuable tool supporting customers in glycoprotein characterization for biotherapeutic development. Therapeutic monoclonal antibodies (IgG, mAb) are routinely expressed in recombinant expression systems. N-glycosylation is one of the most important post-translational modifications. Monitoring of glycosylation in antibody development and…